One of the most significant water efficiency and REUSE projects carried out by an SME in France.
What is a treatment and reuse plant?
With an investment of over €6 million, we are proud to announce the opening of our wastewater treatment plant in September 2024. This plant, which uses reverse osmosis technology, will enable water to be reused for our industrial utilities, a process known in industry parlance as ‘re-use’.
treatment and Reuse?
“Water, like energy, is a scarce resource that poses considerable challenges for manufacturers. Today, it is no longer possible to envisage investment in capacity that would lead to over-consumption of water: manufacturers must therefore do more and do it better for the same amount of water used. It’s a challenge that the whole of industry must rise to.”
Jacques Pidoux, president of BCF Life Sciences
Our REUSE treatment plant is therefore fully in line with these new challenges, as it is the only way we can both manage the capacity constraints of the Pleucadeuc municipal treatment plant and envisage increasing our industrial capacity by 50% within 3 to 4 years.
Water savings of 80 000m3 per year
A 25% reduction in our water withdrawals from the natural environment
Treatment capacity 300m3 of effluent per day
Built and jointly operated with Ovive, this infrastructure will use reverse osmosis technology to produce over 80,000 m3 of REUSE water a year, reducing BCF Life Sciences’ impact on the natural environment by 25%.
How does it work?
Separating salt from treated and filtered effluent
Producing risk-free water for our utilities
Reduce our impact on the natural environment by cutting our water consumption by 25%.
The benefits of reverse osmosis
Reverse osmosis is a filtration system made up of semi-permeable membranes that allow water to pass through but block and reject ions and molecules. At the BCF Life Sciences plant, the role of reverse osmosis is to separate the salt from the treated effluent. The effluent is therefore separated into a stream of pure water (the permeate) and a concentrated discharge (the salt concentrate). The conversion rate of this reverse osmosis process is 85% permeate and 15% retentate. This permeate or pure water is then distributed to the site’s utilities.
in figures
6,1m€
of investment
OUR SCHEDULE
Nov. 2022 : Start of studies (14 months)
May 2023 : Start of works (16 months)
Sept. 2024 : Start of production
Resources required
(6 people)
Industrial customer
(6 people)
Water caterer
(2 people)
Civil engineering
at the heart of BCF Life Sciences' CSR strategy
Scientific demonstration of the contribution of our products to human, animal and plant health
The creation of shared value: in 2019, the opening of an employee shareholding fund enabled the company’s capital to be opened up to employees (80% of employees at the time became shareholders)
Creating economic and social value for our ecosystem (our industry, our employees, our region)
Conservation of resources and energy transition (BCF Life Sciences has set itself the target of reducing its gas and electricity consumption by 30% by 2027 compared with 2021).
